Retrophin Inc. (NASDAQ:RTRX) shares traded down 1.2% during mid-day trading on Thursday . The company traded as low as $16.92 and last traded at $17.02, with a volume of 193,985 shares trading hands. The stock had previously closed at $17.22.

A number of research analysts recently issued reports on the stock. JMP Securities reissued a “buy” rating on shares of Retrophin in a research report on Saturday, July 9th. BMO Capital Markets reissued a “buy” rating on shares of Retrophin in a research report on Wednesday, May 4th. Zacks Investment Research cut shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Finally, Leerink Swann reissued a “buy” rating on shares of Retrophin in a research report on Wednesday, May 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $24.20.

The firm’s 50 day moving average price is $18.07 and its 200-day moving average price is $16.09. The stock has a market capitalization of $625.53 million and a price-to-earnings ratio of 6.92.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.30. The firm had revenue of $33.30 million for the quarter, compared to the consensus estimate of $32.73 million. The company’s revenue for the quarter was up 38.2% compared to the same quarter last year. Equities research analysts predict that Retrophin Inc. will post $0.09 earnings per share for the current year.

In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the business’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $17.75, for a total transaction of $155,312.50. Following the transaction, the executive vice president now owns 167,084 shares in the company, valued at $2,965,741. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Several hedge funds and institutional investors recently bought and sold shares of RTRX. California State Teachers Retirement System boosted its position in Retrophin by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 64,781 shares of the biopharmaceutical company’s stock worth $1,250,000 after buying an additional 1,129 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in Retrophin by 1,449.5% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 91,421 shares of the biopharmaceutical company’s stock worth $1,763,000 after buying an additional 85,521 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Retrophin by 2.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 149,050 shares of the biopharmaceutical company’s stock worth $2,875,000 after buying an additional 3,900 shares during the last quarter.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.